P-glycoprotein expression and antiepileptic drug resistance

The Lancet Neurology

Volumn 12, Issue 8, 2013, Pages 732-733

  French, Jacqueline A ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE 10,11 OXIDE; CLOBAZAM; ETIRACETAM; GLYCOPROTEIN P INHIBITOR; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN; PHENOBARBITAL; PHENYTOIN; TARIQUIDOR; TOPIRAMATE; UNCLASSIFIED DRUG; VIGABATRIN;

ANTICONVULSANT THERAPY; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPORAL LOBE EPILEPSY; UPREGULATION;

EPILEPSY, TEMPORAL LOBE; FEMALE; HUMANS; MALE; P-GLYCOPROTEIN;

EID: 84880326340     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70128-5     Document Type: Letter

References (6)

1. Rogawski MA The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. Epilepsia 2013, 54(suppl 2):33-40.
2. Kwan P, Schachter SC, Brodie MJ Drug-resistant epilepsy. N Engl J Med 2011, 365:919-926.
3. Srivastava AK, White HS Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats. Epilepsy Res 2013, 104:26-34.
4. Brodie MJ, Barry SJ, Bamagous GA, Kwan P Effect of dosage failed of first antiepileptic drug on subsequent outcome. Epilepsia 2013, 54:194-198.
5. Feldmann M, Asselin M-C, Liu J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol 2013, published online June 18. http://dx.doi.org/10.1016/S1474-4422(13)70109-1.
6. Haerian BS, Roslan H, Raymond AA, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure 2010, 19:339-346.